Story perspectives

United Therapeutics Soars 33% Amid Strong Results, Beam Rises 11%

9/3/2025

46 7

Summary

Story summary

United Therapeutics’ stock increased by 33.07% after positive Tyvaso Phase 3 results and UBS raised its price target to $415.
The company reported $798.6M in revenue and a strong EBIT margin of 53.6%.
Beam Therapeutics’ stock rose 11.71% due to FDA designations and positive trial results, despite financial challenges.
Beam's cash reserves reached $1.2B, but it reported a negative profit margin and $8.5M in revenue.
Both companies show growth potential, but Beam needs to resolve financial issues to maintain investor confidence.

1 of 1

Story summary

United Therapeutics’ stock increased by 33.07% after positive Tyvaso Phase 3 results and UBS raised its price target to $415.
The company reported $798.6M in revenue and a strong EBIT margin of 53.6%.
Beam Therapeutics’ stock rose 11.71% due to FDA designations and positive trial results, despite financial challenges.
Beam's cash reserves reached $1.2B, but it reported a negative profit margin and $8.5M in revenue.
Both companies show growth potential, but Beam needs to resolve financial issues to maintain investor confidence.